TIS 0.00% 0.0¢ tissue therapies limited

defer us trials until cashflow, page-30

  1. 2,630 Posts.
    lightbulb Created with Sketch. 4
    Resourced,

    I struggle to know when (if ever) you are serious or more likely simply stirring. However your inane posts on aborting R&D spend are so silly that I reluctantly take the bait.

    R&D cannot be switched on or off on a whim. It is a living and breathing component of any innovative business and should be valued and nurtured. It is R&D spend that brought VitroGro into our world! This molecule and others in our IP suite need to be investigated fully so all options for further development are advanced such that busness cases can be made for commercialisation. We don't have time on our side - it's a competitive world in which we live.

    imo it is better to spend well and effectively than not at all.
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.